ISN
INTERNATIONAL SOCIETY OF NEPHROLOGY

Hosted by

APSN

WCN'26

INDUSTRY SYMPOSIA

E-book

Official WCN'26 sponsored session from Alexion, AstraZeneca Rare Disease

THE COMPLEMENT CONNECTION:

Rethinking Disease Progression in IgA Nephropathy



WCN 2026 Yokohama

Hall 304 **17:00-18:00 JST** **Sunday 29th March**

(Chair) Prof. Hitoshi Suzuki
Juntendo University, Japan

Dr. Shikha Wadhwani
University of Texas, US

Prof. Jonathan Barratt
University of Leicester, UK

AGENDA:

17:00 - 17:02	Welcome and introduction *Prof. Hitoshi Suzuki*
17:02 - 17:22	Understanding IgA nephropathy worldwide: presentation, progression, and epidemiology *Dr. Shikha Wadhwani*
17:22 - 17:42	Mechanistic insights: exploring the role of complement in IgA nephropathy *Prof. Jonathan Barratt*
17:42 - 18:00	Panel discussion and question and answer session, and closing remarks *All faculty*

This official WCN'26 sponsored symposium is fully funded and organised by Alexion, AstraZeneca Rare Disease. This event is intended for healthcare professionals only. Information presented at this industry-sponsored symposium is not necessarily endorsed by the WCN.
M/JP/ULT-a/0140
December 2025

ISN WCN'26

ALEXION AstraZeneca Rare Disease

ISN INTERNATIONAL SOCIETY OF NEPHROLOGY | MARCH 28-31 , 2026 YOKOHAMA JAPAN

Hosted by APSN

WCN'26

You are invited to an official WCN '26 Sponsored Symposium

GLP-1RAs in Kidney Disease:
Mechanisms, Applications in Clinical Practice and the Future

30th MARCH 2026

MONDAY
08:10 - 09:10 AM (GMT+8)

ROOM 301+302

The symposium is accessible via live stream. To join, please click the 'Livestream' link here.

Livestream

AGENDA

- **Welcome & Introduction**
  Chair: Katherine Tuttle
- **Mechanistic effects of semaglutide on kidney disease in type 2 diabetes: The REMODEL trial**
  Presenter: Katherine Tuttle
- **Multiparametric imaging and tissue transcriptomics to unravel mechanisms of kidney protection**
  Presenter: Matthias Kretzler
- **GLP-1RAs in combination with other therapies and applications in clinical practice**
  Presenter: Brendon Neuen
- **The future of GLP-1RAs and other incretin-based therapies for kidney disease**
  Presenter: Masaomi Nangaku
- **Q & A**
  All faculty

The scientific content of this symposium has been developed independently by the ISN

SYMPOSIUM CHAIR AND PRESENTERS

Katherine Tuttle
Division of Nephrology, University of Washington, Seattle, and Providence Medical Research Center, Spokane, WA, USA

Matthias Kretzler
Department of Internal Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA

Brendon Neuen
Department of Renal Medicine, Royal North Shore Hospital, Sydney, and George Institute for Global Health, University of New South Wales, Sydney, Australia

Masaomi Nangaku
Division of Nephrology and Endocrinology, Department of Hemodialysis and Apheresis, University of Tokyo Hospital, Tokyo, Japan

novo nordisk®

This program is sponsored by Novo Nordisk A/S, Denmark

Save the date and join us for

ISN INTERNATIONAL SOCIETY OF NEPHROLOGY | WCN'26

Hosted by JSN APSN

MARCH 28-31, 2026 | YOKOHAMA, JAPAN

Exploring the Role of APRIL in IgA Nephropathy: Pathogenesis to Progression

CHAIR

Yusuke Suzuki, MD, PhD
Juntendo University
Tokyo, Japan

SPEAKER

Heather Reich, CM, PhD, FRCPC
University of Toronto, UHN
Toronto, ON, Canada

SPEAKER

Chee Kay Cheung, MBChB, PhD, FRCP
University Hospitals of Leicester
Leicester, UK

Learning Objectives

- Understand the role of B cells and APRIL in IgAN pathogensis
- Discuss the evolution of IgAN KDIGO guidelines
- Highlight the burden of disease and risk of progression associated with IgAN globally

Date & Time

Sunday, March 29, 2026 | 12:50 PM - 1:50 PM JST

Location

Hall 3F, Room 301 & 302



Official WCN'26 sponsored session.

A non-promotional symposium organized and funded by Otsuka Pharmaceutical Development & Commercialization, Inc. Intended for Healthcare Professionals only. Otsuka is a sponsor of WCN'26.

©2026 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.

Otsuka

Official WCN'26 Sponsored Session

Satellite Symposium at the World Congress of Nephrology (WCN) 2026 Congress

A New Era for Patients with C3G: Redefining Standard of Care

Monday, 30 March 2026 | 12:50–1:50 PM (JST)
Room 503, Pacifico Yokohama, Yokohama, Japan

REGISTER HERE FOR WCN 2026

AGENDA

2 min	**Welcome and introduction** Yoshitaka Isaka (Chair)
5 min	**Presentation: Pathophysiology of C3G and importance of early diagnosis** Yoshitaka Isaka (Chair)
20 min	**Presentation: Case studies: Different patient profiles including transplant patients** Carla M. Nester, David Kavanagh, Paul Brinkkötter
20 min	**Panel discussion: Guidelines and redefining standard of care** All faculty *Moderated by:* Yoshitaka Isaka (Chair)
10 min	**Audience Q&A** All faculty *Moderated by:* Yoshitaka Isaka (Chair)
3 min	**Summary and close** Yoshitaka Isaka (Chair)

FACULTY

CHAIR

Prof. Yoshitaka Isaka
Dept. of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan; Special Advisor to Japanese Society of Nephrology (JSN)

SPEAKERS

Prof. Carla M. Nester
Stead Family Children's Hospital, University of Iowa, Iowa City, IA, USA

Prof. David Kavanagh
National Renal Complement Therapeutics Centre (NRCTC), Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, UK

Prof. Dr. Paul Brinkkötter
Dept II of Internal Medicine, University Hospital of Cologne, Germany

NOVARTIS

© 2026 Novartis Pharma AG
CH-4002 Basel, Switzerland

This symposium is organized and funded by Novartis and is intended for an audience of non-UK HCPs within the context of the World Congress of Nephrology (WCN) 2026 in Yokohama, Japan.

This scientific information may include data/information on investigational uses of compounds/drugs that have not been approved by regulatory authorities.

FUSE MLR ID: 11585823 | January 2026

Official WCN'26 sponsored session

Satellite Symposium at the World Congress of Nephrology (WCN) 2026

EVERY NOTE MATTERS:

COLLECTIVE ACTION TO CHANGE THE TUNE OF IgA NEPHROPATHY

SUNDAY 29 MARCH | 12:50–13:50 JST

Room 503, Pacifico Yokohama, Yokohama, Japan

AGENDA

7 min **Welcome and introduction**
Motoko Yanagita

13 min **Orchestrating excellence: KDIGO's guidance on the management of IgA nephropathy**
Sydney Tang

15 min **Setting the tempo: the importance of early diagnosis and treatment in IgA nephropathy**
María José Soler

15 min **A harmonious approach: simultaneously targeting both drivers**
Vlado Perkovic

7 min **A note of hope: reimagining the outcomes for patients with IgA nephropathy**
Motoko Yanagita

3 min **Summary and close**
Motoko Yanagita

FACULTY

CHAIR

Motoko Yanagita
Kyoto University,
Kyoto, Japan

SPEAKERS

Sydney Tang
University of Hong Kong,
Hong Kong

María José Soler
Hospital Universitari Vall d'Hebron, Barcelona, Spain

Vlado Perkovic
University of New South Wales,
Sydney, NSW, Australia

NOVARTIS

© 2026 Novartis Pharma AG
CH-4002 Basel, Switzerland

JST, Japan Standard Time; KDIGO, Kidney Disease: Improving Global Outcomes.

This symposium is organized and funded by Novartis and is intended for an audience of non-UK healthcare professionals within the context of WCN 2026 in Yokohama, Japan.

01/26 FA-11577588

Industry Symposium by Bayer
'Official WCN'26 sponsored session'

Combination with Confidence: Finerenone for Kidney and Heart Protection

Monday, March 30, 2026, 12:50–13:50 JST
Location: Room 501 + 502

Naoki Sato
(Cardiologist, Japan)

Brendon Neuen
(Nephrologist, Australia)

Rajiv Agarwal
(Nephrologist, USA)

Jozine Ter Maaten
(Cardiologist, Netherlands)

Keizo Kanasaki
(Diabetologist, Japan)

Time	Title	Speaker
12:50–12:55	**Welcome and introduction**	Naoki Sato
12:55–13:05	**Early action, stronger protection**	Brendon Neuen
13:05–13:20	**Lower UACR, optimized outcomes**	Rajiv Agarwal
13:20–13:30	**Finerenone, a CKM care pillar**	Jozine Ter Maaten
13:30–13:40	**Changing trajectories in practice**	Keizo Kanasaki
13:40–13:50	**Q&A and closing remarks / panel discussion (voting)**	Rajiv Agarwal & Naoki Sato

For healthcare professionals only.

January 2026
PP-KER-JP-2609-18-01

Join Boehringer Ingelheim at our official WCN'26 sponsored session

Beyond the kidneys: the importance of early intervention and managing cardiovascular risk in patients with CKD

Time: Monday 30 March 2026, 17:00–18:00 (JST)
Location: Room 301 + 302

Through an engaging and interactive discussion, our esteemed faculty will focus on the importance of early intervention and managing the elevated cardiovascular risk in patients with CKD[1]

Agenda highlights:

- **From evidence to practice:** SGLT2 inhibitors as a foundational treatment for patients with CKD, (12 minutes)
- **Prompt action in CKD:** increasing treatment benefits for your patients with CKD, (15 minutes)
- **The hidden burden:** managing cardiovascular risk in patients with CKD, (13 minutes)
- Audience Q&A, (10 minutes)

Doctor
Takashi Yokoo (chair),
Japan

Doctor
Ian de Boer,
USA

Doctor
Beatriz Fernández-Fernández,
Spain

Doctor
Brendon Neuen,
Australia

Date of preparation: January 2026 | PC-JP-126412

1. Jankowski J *et al. Circulation* 2021;143:1157

CKD, chronic kidney disease; SGLT2, sodium-glucose co-transporter-2

Boehringer Ingelheim

Official WCN'26 sponsored session

By Viatris Pharmaceuticals Japan G.K. Medical Affairs

Industry Symposia Slot58

Rethinking IgA Nephropathy

Through Mucosal Immunity : Integrating Tonsillar & Intestinal Perspectives

Date

Monday, March 30, 2026
17:00-18:00

Venue

Pacifico Yokohama Room 503
1-1-1 Minatomirai, Nishi-ku, Yokohama-shi, Kanagawa Prefecture, Japan

Chair

Hitoshi Suzuki
Professor of Department of Nephrology and Hypertension,
Juntendo University Urayasu Hospital

Tonsillectomy for IgA nephropathy

Speaker

Miki Takahara
Professor of Department of Otolaryngology,
Head and Neck Surgery, Asahikawa Medical University

Impact of intestinal barrier dysfunction on IgA deposition in the glomeruli

Speaker

Koji Hase
Professor of Department of Pharmaceutical Sciences, Keio University

A light boxed meal will be provided for attendees (limited quantity available).

VIATRIS

MA-JP-Nephrology-01/26-00001

ISN INTERNATIONAL SOCIETY OF NEPHROLOGY | WCN'26

Hosted by ISN APSN

MARCH 28-31, 2026 | YOKOHAMA, JAPAN

World Congress of Nephrology

Morning Seminar

Room 304

Date March. 29, 2026 (Sun.) 8:10-9:10

Venue Pacific Convention Plaza Yokohama (PACIFICO Yokohama)
1-1-1, Minato Mirai, Nishi-ku, Yokohama 220-0012, JAPAN

URIC ACID and KIDNEY DISEASE

Chair

Akira Nishiyama, M.D., Ph.D. Professor
Dean, Faculty of Medicine Kagawa University Graduate School of Medicine

Mariko Miyazaki, M.D., Ph.D. Associate Professor
Department of Nephrology Tohoku University Graduate School of Medicine

Topic 01

Urinary uric acid excretion and kidney outcome

Yoshitaka Isaka, M.D., Ph.D. Professor
Department of Nephrology The University of Osaka Graduate School of Medicine

Topic 02

Uric acid and progression of DKD

Jun Wada, M.D., Ph.D. Professor
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University

Official WCN'26 sponsored session
Organized by Mochida Pharmaceutical Co.,Ltd./Fujiyakuhin Co.Ltd.

World Congress of Nephrology 2026
SLOT4 (Official WCN'26 sponsored session)

Date and Time 08:10–09:10 Sunday **March 29**, 2026

Venue Room 503, Pacifico Yokohama 5F
1-1-1 Minatomirai, Nishi Ward, Yokohama, Kanagawa 220-0012, Japan

Program

Chairperson Prof **Daniel T M Chan**
Chair Professor, University of Hong Kong

Presentation 1 08:10–08:40

Intestinal Phosphate Absorption Mechanisms UpToDate -Tenapanor and Future Perspectives-

Lecturer **Hiroko Segawa**
Professor, Department of Applied Nutrition,
Tokushima University Graduate School of Biomedical Sciences

Presentation 2 08:40–09:10

CKD-MBD Guideline Revision in Japan: The Journey and Global Implications

Lecturer **Hirotaka Komaba**
Professor, Department of Nephrology, Endocrinology and Metabolism,
Tokai University School of Medicine

Organized by Kyowa Kirin Co., Ltd.

OFFICIAL WCN'26 SPONSORED SESSION

sobi
rare strength

New horizons in C3G and primary IC-MPGN:



navigating the future of patient care

Monday 30 March 2026, 08.10–09.10 AM JST
Room 503, Pacifico Yokohama

Join our expert panel as they explore how the evolution of C3G (complement 3 glomerulopathy) and primary IC-MPGN (immune complex-mediated membranoproliferative glomerulonephritis) understanding has informed patient care today. Through patient cases and panel discussion, the faculty will share their insights into optimising patient management, from achieving early diagnosis to navigating a new standard of care.

Expert panel

Shoichi Maruyama
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Edwin Wong
National Renal Complement Therapeutics Centre, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK

Seung Hyeok Han
Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea

Agenda

Chair's welcome	Shoichi Maruyama (Japan)
Evolution of C3G and primary IC-MPGN disease understanding: from molecular mechanisms to addressing patient needs	Edwin Wong (UK)
A race against time: the value of an early and accurate diagnosis	Seung Hyeok Han (Republic of Korea)
Panel discussion Looking to the future: time to support our patients	All speakers Moderated by: Shoichi Maruyama (Japan)
Q&A and close	All speakers Moderated by: Shoichi Maruyama (Japan)

Sobi is a trademark of Swedish Orphan Biovitrum AB (publ) ©2026 Swedish Orphan Biovitrum AB (publ) – All rights reserved
This medical education session has been organised and funded by Sobi™ and is intended for healthcare professionals
Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden. www.sobi.com
Date of preparation: January 2026 NP-46622

ISN WCN'26 MARCH 28-31, 2026 YOKOHAMA JAPAN

AstraZeneca

Official WCN'26 sponsored session
Industry Symposium

PROGRAM

The significance of potassium management in CKD treatment

Chair

Professor, Department of Nephrology,
Kyoto University Graduate School of Medicine

Dr. Motoko Yanagita

Speaker

Professor, Department of Nephrology,
Kumamoto University Graduate School of Medical Sciences

Dr. Hideki Yokoi

Date

Monday March 30, 2026
17:00～18:00

Venue

Pacifico Yokohama,
Room 303

AstraZeneca

ISN MARCH 28-31, 2026 YOKOHAMA JAPAN

WCN'26

Official WCN '26 sponsored session

Date Sunday March 29, 2026 17:00-18:00

Venue Room 501+502, Pacifico Yokohama

1-1-1 Minatomirai, Nishi Ward, Yokohama, Kanagawa, 220-0012, Japan

Transformative Insights from the DAPA-CKD Trial: Lessons for the Future of Kidney Care

Chair **Yoshitaka Isaka**, MD, PhD

Professor, Department of Nephrology,
The University of Osaka Graduate School of Medicine

Speaker **Naoki Kashihara**, MD, PhD

Director, Kawasaki Geriatric Medical Center

ISN WCN'26 MARCH 28-31, 2026 YOKOHAMA JAPAN Hosted by JAPSN

Official WCN'26 sponsored session

Industry Symposium #13

ゼリア新薬 ZERIA

Hyperkalemia in CKD and Heart Failure

Including Q & A and discussion sessions

【Date】Sunday, 29 March 2026
【Time】12:50 in the afternoon to 1:50 pm
【Venue】Room 315, 3rd floor in PACIFICO YOKOHAMA

Chair

Kei Fukami,
Professor, Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Japan

Speaker 1

The importance of Guideline Directed Therapy

Christoph Wanner,
Professor of Medicine, University Hospital Würzburg, Department of Clinical Studies and Epidemiology, Comprehensive Heart Failure Center, Germany

Speaker 2

Long-term management of Hyperkalemia with safety

Naoki Kashihara,
Professor of Kawasaki Medical School, Japan
Director of the Kawasaki Geriatric Medical Center
President of Japan Kidney Association,
Immediate past president of Japanese Society of Nephrology

Zeria Pharmaceutical Co., Ltd.

WCN'26
Industry Symposia slot 1

Official WCN' 26 sponsored session

March 29, 2026 (Sunday) 8:10-9:10
Room 315
PACIFICO Yokohama Conference Center 3F
1-1-1 Minatomirai, Nishi-ku, Yokohama

Comprehensive management of Chronic Kidney Disease: Insights from Japan

Chair

Masaomi Nangaku, MD, PhD
Professor, Division of Nephrology and Endocrinology,
The University of Tokyo Graduate School of Medicine, Japan

Lecture 1



Advanced Data Science in CKD Management

Yuichiro Yano, MD, PhD
Professor, Department of General Medicine, Juntendo University Faculty of Medicine, Japan
Director, Artificial Intelligence Incubation Farm, Juntendo University Faculty of Medicine, Japan
Director/Founder, Department of Medical AI and Digital Innovation (MID), Japan

Lecture 2

An Integrated Approach to Cardio-Renal-Metabolic Disorders: Addressing Hypertension and Dyslipidemia

Kouichi Tamura, MD, PhD
Professor, Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan
Director, Yokohama City University Medical Center, Japan

The topics will cover the followings:

1. Big data analysis using medical registry databases (J-CKD-DB etc.)
2. Predictive model for renal function utilizing real world data and generative AI
3. New target, ATRAP, as a novel player in hypertension and beyond
4. Importance of lipid management: insights from epidemiology and future perspectives

ISN WCN'26 MARCH 28-31, 2026 | YOKOHAMA, JAPAN

Kowa Company, Ltd.

Official WCN'26 sponsored session

Bringing innovative CKD treatments to patients without delay:

Barriers and Solutions

Session Date Sunday, March 29, 2026 8:10–9:10 AM

Session Room ROOM 301+302

SESSION DESCRIPTION (total 60 min)

1. Lecture Chairs: Prof. Hiddo Lambers Heerspink / Prof. Naoki Kashihara 30min

Topic 1 [10min]

Clinical impacts and importance of minimizing drug approval delay

- Prof. Naoki Kashihara | Professor, Kawasaki Medical School, Japan

Topic 2 [10min]

HCE and eGFR slope, as potential solutions to delays in approval

- Prof. Hiddo Lambers Heerspink | Professor, University Medical Center Groningen, Netherlands

Topic 3 [10min]

Bridging Academia and Regulators in Kidney Drug Development: Insights from Japan

- Assoc. Prof. Mototsugu Tanaka | Associate Professor, Niigata University, Japan

2. Panel Discussion and Q&A Chair: Dr. Dustin Little | Astrazeneca, USA 30min

Each to give perspectives of each roles / positions and discuss barriers and solutions.

Discussant: Prof. Heerspink, Prof. Kashihara and Assoc. Prof.Tanaka

AstraZeneca

Industry Symposium

World Congress of Nephrology 2026 - Yokohama

Pediatric Nephrotic Syndrome

March 29, 2026 (Sun) 8:10-9:10

PACIFICO Yokohama Conference Center 3F 303

1-1-1, Minato Mirai, Nishi-ku, Yokohama 220-0012, JAPAN

Chair

Dr. Kaori Hayashi
Professor, Department of Nephrology, Endocrinology and Metabolism,
Keio University School of Medicine

Speaker 1

Dr. Tomoko Horinouchi
Associate Professor, Department of Pediatrics,
Kobe University Graduate School of Medicine

Impact of Anti-Nephrin Antibodies: An Updated Understanding of the Pathogenesis of Nephrotic Syndrome

Speaker 2

Dr. Riku Hamada
Department of Nephrology and Rheumatology,
Tokyo Metropolitan Children's Medical Center

Recent advances in Immunosuppressive Therapy for Refractory Nephrotic Syndrome in Children

Official WCN'26 sponsored session

CHUGAI PHARMACEUTICAL
A member of the Roche group

World Congress of Nephrology 2026

Industry Symposia Slot 18

Hypertension Management Aimed at Achieving Target Blood Pressure

: The Clinical Utility of Mineralocorticoid Receptor Antagonists

Chair

Prof. Shigeru Shibata
Division of Nephrology, Department of Internal Medicine,
Teikyo University School of Medicine

Speaker

Assoc. Prof. Hajime Nagasu
Department of Nephrology and Hypertension,
Kawasaki Medical School

3/29 (Sun)

Date | **Sunday, March 29, 2026**
12:50~13:50

Venue | **Room 501+502** (PACIFICO Yokohama)
1-1-1 Minatomirai, Nishi-ku, Yokohama-shi,
Kanagawa Prefecture, 220-0012, Japan

Daiichi-Sankyo

Official WCN'26 Sponsored Session / Daiichi Sankyo Company, Limited

World Congress of Nephrology 2026

Industry Symposia Slot 61

Revisiting MR-Mediated Electrolyte Imbalance at the Tissue Level

: Implications for MR Blockade and JSH2025 Guidelines

Chair

Prof. Motoko Yanagita
Department of Nephrology, Graduate School of Medicine, Kyoto University

Speaker

Asst. Prof. Kento Kitada
Department of Pharmacology, Faculty of Medicine, Kagawa University

3/31 (Tue)

Date | **Tuesday, March 31, 2026**
8:00~9:00

Venue | **Room 303** (PACIFICO Yokohama)
1-1-1 Minatomirai, Nishi-ku, Yokohama-shi, Kanagawa Prefecture, 220-0012, Japan

Daiichi-Sankyo

Official WCN'26 Sponsored Session / Daiichi Sankyo Company, Limited

CHUGAI PHARMACEUTICAL

A member of the Roche group

Industry Symposium

WORLD CONGRESS OF NEPHROLOGY 2026 - YOKOHAMA

EVOLVING LANDSCAPE OF IGA NEPHROPATHY IN 2026 AND BEYOND

MARCH 29, 2026 (SUN) 17:00-18:00

PACIFICO YOKOHAMA CONFERENCE CENTER 3F 303

1-1-1, Minato Mirai, Nishi-ku, Yokohama 220-0012, JAPAN

CHAIR

Dr. Yusuke Suzuki

Professor, Department of Nephrology,
Juntendo University Faculty of Medicine

SPEAKER

Dr. Hong Zhang

Professor of Internal Medicine, Director of Renal division,
Peking University First Hospital

Official WCN'26 sponsored session

KDIGO presents

The Importance of Targeting IgAN Disease Drivers: Real-World Practice Using Case-based Illustrations

MONDAY, MARCH 30, 2026
12:50 – 13:50 HRS JST
ROOM 301 + 302 • PACIFICO YOKOHAMA

EXPERT SPEAKERS

BRAD ROVIN
The Ohio State University, USA

HONG ZHANG
Peking University First Hospital, China

HITOSHI SUZUKI
Juntendo University, Japan

Official WCN'26 Sponsored Symposium
Supported by an educational grant from Otsuka

Biogen



Addressing unmet needs in immune-mediated kidney diseases

ONE ANTIBODY AT A TIME.

Join our official WCN'26 sponsored session on March 29th from 12:50 - 1:50 PM in Room 303

This symposium explores a unifying, mechanism-based framework for treating immune-mediated kidney diseases grounded in shared biology. Despite differences across IgA nephropathy (IgAN), primary membranous nephropathy (PMN) and antibody-mediated rejection (AMR) following kidney transplantation, these diseases converge on a common immunological basis, plasmablasts, plasma cells, and NK cells. This session will review emerging evidence which suggests that targeting these cells directly may offer an effective and durable therapeutic strategy.

Yoshihito Nihei, MD PhD
Juntendo University
Tokyo, Japan

Vivek Jha, MD DM FRCP FAMS
The George Institute for Global Health
New Delhi, India

Steven Chadban, BMed PhD FRACP FAHMS
University of Sydney
Sydney, Australia

Biogen-280084 | January 2026

COME VISIT BIOGEN AT BOOTH #25

World Congress of Nephrology 2026
Industry Symposium

Date：Monday, March 30, 2026 / 17:00-18:00
Venue：Room 315 (3F, Conference Center), PACIFICO YOKOHAMA
1-1-1 Minato Mirai, Nishi-ku, Yokohama 220-0012, Japan

Theme "Comprehensive Management of Fabry Disease: Latest Evidence from Korea and Japan"

Chair **Dr. Kei Fukami**
Chief Professor, Division of Nephrology, Department of Medicine,
Kurume University School of Medicine, Japan

Opening Remarks **Dr. Kei Fukami**

＜Scientific Presentation 1＞

"Optimal Timing of Treatment Initiation and Monitoring Strategies for Fabry Disease Patients in Korea"

Speaker 1 **Dr. Eun Hui Bae**
Department of Internal Medicine, Chonnam National University Medical School;
Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea

＜Scientific Presentation 2＞

"New Therapeutic Strategies for Fabry Disease"

Speaker 2 **Dr. Hideki Fujii**
Division of Nephrology, Kobe University Graduate School of Medicine, Japan

Discussion Theme "Optimizing Patient Care: Lessons from Japan and Korea"

Closing Remarks **Dr. Kei Fukami**

sanofi

Official WCN'26 sponsored session

ISN MARCH 28-31, 2026 YOKOHAMA JAPAN
WCN'26
Official WCN' 26 sponsored symposium

zydus
Dedicated To Life

Reimagining Anemia Management in CKD: Evolution with HIF-PHIs

30th March 2026 | 12.50 pm - 1.50 pm | Hall 315

CHAIRPERSON
Dr. Ashok Sarin
Indraprastha Apollo Hospitals, New Delhi, India.

SPEAKER
Dr. (Prof.) P P Varma
Venkateshwar Hospital, New Delhi, India.

SPEAKER
Dr. (Prof.) Dinesh Khullar
Max Super Specialty Hospital, Saket, New Delhi, India.

MODERATOR
Dr. (Prof.) Manish Malik
Sir Ganga Ram Hospital, New Delhi, India.

PANELISTS

Dr. (Prof.) Narayan Prasad
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.

Dr. Sandip Kumar Bhattacharya
Apollo Multispeciality Hospital, Kolkata, India.

Dr. (Prof.) Dibya Singh Shah
Tribhuvan University Teaching Hospital, Kathmandu, Nepal.

Dr. (Prof.) D S Bhadauria
Medanta Hospital, Lucknow, India.

AGENDA

DURATION	TOPIC	SPEAKER/PANELIST	CHAIRPERSON
15 min.	Paradigm Shift in Anemia Management: From ESAs to HIF-PHIs	Dr. (Prof.) P P Varma	Dr. Ashok Sarin
15 min.	Real-World Evidence with Desidustat: India's Contribution to the Global HIF Story	Dr. (Prof.) Dinesh Khullar	
30 min.	**Panel Discussion-** Optimizing Outcomes with HIF-PHIs in CKD Anemia	Dr. (Prof.) Narayan Prasad Dr. Sandip Kumar Bhattacharya Dr. (Prof). Dibya Singh Shah Dr. (Prof.) D S Bhadauria	**Moderator:** Dr. (Prof.) Manish Malik

This symposium is supported by an unrestricted educational grant from Zydus Lifesciences Ltd.

eleva

Complement-Mediated Kidney Disease:

From Mechanisms to Therapies

March 30, 2026
08:10 – 09:10 am

Room 315
Official WCN'26 sponsored session

CHAIR

Prof. Dr. Christine Skerka
Koania Complement Analytics, Hamburg, Germany

SPEAKERS

Prof. Dr. Peter F. Zipfel
Koania Complement Analytics, Hamburg, Germany

Complement Deregulation in C3 Glomerulopathy: A Diagnostic Perspective

Prof. Dr. Michael Wiesener
Senior Physician, Specialist in Internal Medicine and Nephrology
University Hospital, Erlangen, Germany

Targeted Therapy for C3 Glomerulopathy: Exciting Changes for Patients and Nephrologists

Dr. Dinesh Khullar
Chairman Nephrology & Renal Transplant Medicine
Max Superspeciality Hospital Saket, New Delhi, India

C3 Glomerulopathy: Current Concepts and Emerging Therapeutic Strategies

vera therapeutics®

ISN WCN'26 MARCH 28-31, 2026 YOKOHAMA JAPAN



Official WCN'26 Sponsored Session

Emerging Therapeutic Approaches in IgA Nephropathy:

Innovations in B-Cell Modulation and Dual BAFF/APRIL Inhibition

Monday, March 30, 8:10 – 9:10 AM

Pacifico Yokohama National Convention Hall
Meeting Room 501-502

Agenda

Opening Remarks
Hitoshi Suzuki, MD, PhD *(Japan)*

Overview of the Unmet Need in IgA Nephropathy and Key Disease Markers
Adrian Liew, MD *(Singapore)*

Emerging Therapeutic Targets in IgAN: Role of Cytokines BAFF and APRIL
Suceena Alexander, MD, DM, PhD *(India)*

Targeting BAFF and APRIL with Atacicept
Richard Lafayette, MD *(United States)*

All speakers have been compensated by Vera for their participation.
Atacicept is an investigational agent and it is not approved for any use by any health authority.
MED-GO-ATAC-0007

Industry Symposium by Boehringer Ingelheim
Official WCN'26 sponsored session

Chronic Kidney Disease in Children:

Challenges of Diagnosis, Screening, and Management

Monday March 30, 2026
08:10–09:10 JST
Room 304

Prof. Jun Oh (Chair)
KfH Kidney Center for Children and Adolescents Hamburg, Germany; Department of Pediatric Nephrology, Pediatric Gastroenterology, and Pediatric Transplantation, University Hamburg/Eppendorf, Germany.



Prof. Kenji Ishikura
Department of Pediatrics, Kitasato University School of Medicine, Tokyo, Japan.

Prof. Hugh McCarthy
Children's Hospital Westmead, University of Sydney, Sydney, NSW, Australia; Sydney Children's Hospitals Network, Sydney, NSW, Australia.

AGENDA

Welcome and introduction *(5 mins)*	Prof. Jun Oh
The burden of pediatric chronic kidney disease: Epidemiology, etiology and unmet needs *(10 mins)*	Prof. Kenji Ishikura
Studying pediatric chronic kidney disease: Challenges in evidence generation and clinical research *(10 mins)*	Prof. Hugh McCarthy
The long-term consequences of childhood CKD: Growth, cardiovascular risk and adult outcomes *(20 mins)*	Prof. Jun Oh
Summary *(5 mins)*	Prof. Jun Oh
Discussion and Q&A *(10 mins)*	All

We look forward to seeing you at this session and encourage your participation in the interactive discussion with the faculty!

Breakfast will be provided to attendees.

Session open to healthcare professionals only.

Please refrain from recording, photographing, or sharing information presented during this industry symposium on social media or other publicly accessible platforms.

SC-CRP-19267

Boehringer Ingelheim

Vantive

Shared Decision-Making (SDM) in Dialysis: Turning Conversations into Care

Lunch Symposium

Sunday, 29 March 2026 | **12:50 PM–01:50 PM*** | **Pacifico Yokohama, Room 304**

Join us for a Lunch Symposium at **the World Congress of Nephrology 2026, Yokohama, Japan.**

This session will highlight the importance of providing balanced modality education, including peritoneal dialysis, to empower patients to choose the therapy that best aligns with their life goals. We will also explore gaps in current practice and practical approaches to make shared decision-making a reality.

Chairperson

Prof. Edwina Brown
(UK)

Speakers

Prof. Tsutomu Furuzono
(Japan)

Prof. Yasuhiro Komatsu
(Japan)

LOCAL TIME*	PROGRAM	SPEAKER
12:50 PM–12:55 PM	Welcome & Introduction	Prof. Edwina Brown (UK)
12:55 PM–01:05 PM	A Patient's Perspective: What SDM Really Means for Me	Prof. Tsutomu Furuzono (Japan)
01:05 PM–01:20 PM	Why SDM in Dialysis Still Falls Short: Understanding the Gaps	Prof. Yasuhiro Komatsu (Japan)
01:20 PM–01:40 PM	Breaking Through Barriers: Practical Strategies to Make SDM Work	Prof. Edwina Brown (UK)
01:40 PM–01:50 PM	Q&A and Closing Remarks	Entire Speaker Panel & Prof. Edwina Brown

Please contact your local Vantive representatives for registration.

Lunch will be provided for attendees, subject to availability.

*JAPAN STANDARD TIME (JST)

© 2026 VANTIVE. ALL RIGHTS RESERVED. FOR HEALTHCARE PROFESSIONALS ONLY.

VANTIVE JAPAN
GRANPARK TOWER 30F, 3-4-1, SHIBAURA, MINATO-KU, TOKYO 108-0023 JAPAN

AP-RC00-260006 (V1.0)

Official WCN'26 sponsored session

ISN INTERNATIONAL SOCIETY OF NEPHROLOGY

WCN'26 Hosted by APSN

World Congress of Nephrology 2026

EVENING SEMINAR

Monday March 30 2026 17:00-18:00

Venue Room 304 Pacifico Yokohama
1-1-1 Minatomirai Nishi-ku, Yokohama-shi, Kanagawa-ken 220-0012 Japan

Theme New trends in Lupus Nephritis

Chair Prof. Masaomi Nangaku
Division of Nephrology and Endocrinology,
The University of Tokyo Graduate School of Medicine

Speaker I 20min Prof. Shoichi Maruyama
Department of Nephrology,
Nagoya University Graduate School of Medicine

The Future of Lupus Nephritis: Achieving Renal Protection Through Proteinuria Control

Speaker II 40min Prof. Keiju Hiromura
Department of Nephrology and Rheumatology,
Gunma University Graduate School of Medicine

A New Era in Lupus Nephritis: Clinical Evidence and Therapeutic Positioning of Triple Therapy

Official WCN'26 sponsored session

Otsuka

calliditas THERAPEUTICS
an AsahiKASEI company

Official WCN'26 sponsored session

The Evolving IgAN Treatment Paradigm- Why target the gut?

March 30, 2026 | 12:50 PM–1:50 PM
Room 303

Yusuke Suzuki, MD, PhD
Department of Nephrology
Juntendo University
Tokyo, Japan
Moderator

Sayna Norouzi, MD, FASN
Division of Nephrology
Loma Linda University
Medical Center
Loma Linda, CA, USA

Chee Kay Cheung, PhD, MRCP
University Hospitals of
Leicester NHS Trust
Leicester, UK

This program explores the evolution of IgAN management, moving beyond traditional supportive care to modern, targeted interventions rooted in the "4-hit hypothesis." Participants will gain insights into the latest clinical guideline updates and learn how to integrate novel therapeutic agents into a personalized treatment strategy.

Time	Topic	Presenter
12:50–1:00 PM	Welcome-Intro and pathophysiology, 4-hit	Yusuke Suzuki, MD, PhD Moderator
1:00–1:15 PM	Audience polling	Chee Kay Cheung, PhD, MRCP
1:15–1:30 PM	Recent guidelines updates in IgAN- The rationale	Chee Kay Cheung, PhD, MRCP
1:30–1:45 PM	The old and the new to approaching treatment	Sayna Norouzi, MD, FASN
1:45–1:50 PM	Summary and close	Yusuke Suzuki, MD, PhD Moderator

MED-US-IgAN-2600012

Visit us at IgANexus Booth #7

Official WCN'26 sponsored session

Trends in global kidney care

Sunday 29 March 2026

Room 315
5pm - 6pm

The World Health Organisation's 2025 recognition of CKD as a global health priority calls for collaborative action. This DaVita symposium showcases impactful initiatives in screening, diagnosis, and treatment making a difference worldwide. Our expert speakers examine CKD management in Africa and ESKD care quality in South America. Discover how we can collectively advance kidney care across continents.

Presentations:

Improving ESKD outcomes in Brazil
Dr Bruno Zawadzki
DaVita Brazil

Identifying and managing CKD in Africa
Dr Kate Bramham
King's College London

Chairs:

Dr Partha Das
DaVita International

Prof. Sharlene Greenwood
King's College London

Visit us at Booth 40

Industry Symposium by Boehringer Ingelheim
Official WCN'26 sponsored session

CKD in focus

Enhancing risk detection and management approaches

Monday 30 March 2026
12:50–13:50 JST
Room 304

Lunch will be provided to attendees. This session is open to healthcare professionals only.

Would you like to gain critical insights to improve CKD detection and treatment?

Join our faculty in this symposium as they delve into the relevance of UACR as an important CV risk marker and explore how to implement optimized use of UACR/UPCR testing. Gain insights into the impact of RAAS dysregulation on cardiorenal pathophysiology and guiding innovative therapeutic approaches.

Prof. Masaomi Nangaku
Professor, Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Dr. Roberto Pecoits-Filho
Distinguished Research Scienstist, Arbor Research Collaborative for Health, Ann Arbor, MI, USA; Professor of Nephrology, University of Michigan, USA

Dr. Pamela Kushner
Clinical Professor, UC Irvine Medical Center, Orange, CA, USA; Director, Kushner Wellness Center, Orange, USA

Prof. Sydney Tang
Chair of Renal Medicine and Yu Professor in Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China

AGENDA

Welcome and introductions	Prof. Masaomi Nangaku
UACR: The hidden marker of heart and kidney risk	Dr. Roberto Pecoits-Filho, Dr. Pamela Kushner
Panel discussion and Q&A	Chaired by Prof. Masaomi Nangaku
The impact of RAAS dysregulation in cardiorenal disease	Prof. Sydney Tang
Panel discussion and Q&A	Chaired by Prof. Masaomi Nangaku
Closing remarks	Prof. Masaomi Nangaku

We look forward to seeing you at this session and encourage your participation in the interactive discussion sessions with the faculty!

Boehringer Ingelheim

Life forward

Please refrain from posting information shared during this symposium on social media or other platforms available to the general public.

SC-CRP-19218 I February 2026

ISN INTERNATIONAL SOCIETY OF NEPHROLOGY

MARCH 28-31 , 2026
YOKOHAMA
JAPAN

Hosted by APSN

WCN'26

Official WCN'26 sponsored session

Targeting pathogenic IgA in IgA Nephropathy

Sunday, **March 29**, 2026

Rooms: **501+502**

Chair / Speaker
Jonathan Barratt (UK)

Speaker
Heather Reich (Canada)

Speaker
Yusuke Suzuki (Japan)

What makes IgA pathogenic in IgA nephropathy?

8:10 AM - 8:25 AM ||| Speaker | **Yusuke Suzuki** (Japan)

The role of B Cells in IgA nephropathy

8:25 AM - 8:40 AM ||| Speaker | **Heather Reich** (Canada)

Targeting pathogenic IgA in IgA nephropathy

8:40 AM - 8:55 AM ||| Speaker | **Jonathan Barratt** (UK)

This symposium is supported with an educational grant from Takeda. Independent scientific content for this symposium has been provided by ISN.

©2026 Takeda Pharamaceutical Company Limited. All rights reserved.
TAKEDA and Takeda are registered trademarks of Takeda Pharmaceutical Company Limited
VV-MEDMAT-133994 | 02/2026

Takeda